WO2002094315A3 - Myostatin immunoconjugate and its use for immunisation - Google Patents

Myostatin immunoconjugate and its use for immunisation Download PDF

Info

Publication number
WO2002094315A3
WO2002094315A3 PCT/US2002/021862 US0221862W WO02094315A3 WO 2002094315 A3 WO2002094315 A3 WO 2002094315A3 US 0221862 W US0221862 W US 0221862W WO 02094315 A3 WO02094315 A3 WO 02094315A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunisation
myostatin immunoconjugate
myostatin
immunoconjugate
avians
Prior art date
Application number
PCT/US2002/021862
Other languages
French (fr)
Other versions
WO2002094315A2 (en
Inventor
Halawani Mohamed E El
Seungkwon You
Original Assignee
Univ Minnesota
Halawani Mohamed E El
Seungkwon You
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Halawani Mohamed E El, Seungkwon You filed Critical Univ Minnesota
Priority to EP02752252A priority Critical patent/EP1387695A2/en
Priority to CA002433644A priority patent/CA2433644A1/en
Priority to AU2002339419A priority patent/AU2002339419A1/en
Publication of WO2002094315A2 publication Critical patent/WO2002094315A2/en
Publication of WO2002094315A3 publication Critical patent/WO2002094315A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Abstract

A method to alter the phenotype of animals, e.g., avians, which employs passive and active immunization with a myostatin immunoconjugate, is provided.
PCT/US2002/021862 2001-01-04 2002-01-04 Myostatin immunoconjugate and its use for immunisation WO2002094315A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02752252A EP1387695A2 (en) 2001-01-04 2002-01-04 Myostatin immunoconjugate and its use for immunisation
CA002433644A CA2433644A1 (en) 2001-01-04 2002-01-04 Myostatin immunoconjugate and its use for immunisation
AU2002339419A AU2002339419A1 (en) 2001-01-04 2002-01-04 Myostatin immunoconjugate and its use for immunisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/754,826 2001-01-04
US09/754,826 US7037501B2 (en) 2001-01-04 2001-01-04 Myostatin immnoconjugate

Publications (2)

Publication Number Publication Date
WO2002094315A2 WO2002094315A2 (en) 2002-11-28
WO2002094315A3 true WO2002094315A3 (en) 2003-02-20

Family

ID=25036517

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021862 WO2002094315A2 (en) 2001-01-04 2002-01-04 Myostatin immunoconjugate and its use for immunisation

Country Status (5)

Country Link
US (2) US7037501B2 (en)
EP (1) EP1387695A2 (en)
AU (1) AU2002339419A1 (en)
CA (1) CA2433644A1 (en)
WO (1) WO2002094315A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp A follistatin domain containing protein
EP1572934A4 (en) * 2002-02-21 2007-12-19 Wyeth Corp Follistatin domain containing proteins
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CA2526669A1 (en) * 2003-06-02 2004-12-16 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
JP2007535912A (en) * 2003-12-31 2007-12-13 シェーリング−プラウ・リミテッド Neutralizing epitope-based growth-enhancing vaccine
AR051853A1 (en) * 2004-12-30 2007-02-14 Schering Plough Ltd VACCINE TO INCREASE GROWTH BASED ON NEUTRALIZING EPITOPES
DK1915397T3 (en) 2005-08-19 2015-04-20 Wyeth Llc Antagonist AGAINST GDF-8 AND USES IN TREATMENT OF ALS AND OTHER GDF-8-ASSOCIATED DISEASES
EP1798292A1 (en) * 2005-12-19 2007-06-20 Nutreco Nederland B.V. Methods for improving turkey meat production
TW200800257A (en) * 2006-06-22 2008-01-01 Genereach Biotechnology Corp Non-genetic engineering promotion growth method and its vaccine is provided
KR102079921B1 (en) * 2007-06-01 2020-02-21 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 Vaccine for the prevention of breast cancer relapse
US8321012B2 (en) * 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
KR20150108405A (en) * 2013-02-22 2015-09-25 조에티스 서비시즈 엘엘씨 In ovo administration of growth factors for improving poultry performance
US10400013B2 (en) 2016-10-26 2019-09-03 Chao-Wei Liao Fusion polypeptide for immuno-enhancement and method for enhancing stimulation of immune response using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
WO1999042573A1 (en) * 1998-02-19 1999-08-26 Biostar Inc. Immunological methods to modulate myostatin in vertebrate subjects
WO2001005820A2 (en) * 1999-07-20 2001-01-25 Pharmexa A/S Method for down-regulating gdf-8 activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128127A (en) 1989-02-08 1992-07-07 Stolle Research & Development Corp. Increased protein production in animals
US5185148A (en) 1991-12-16 1993-02-09 Mycogen Corporation Process for controlling scarab pests with Bacillus thuringiensis isolates
US5554534A (en) 1991-12-16 1996-09-10 Mycogen Corporation Bacillus thuringiensis toxins active against scarab pests
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
JPH09507829A (en) 1993-03-19 1997-08-12 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン Growth differentiation factor-8
WO1998033887A1 (en) 1997-02-05 1998-08-06 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
PT2045322E (en) 1997-07-14 2015-10-16 Université de Liège Double-muscling in mammals
WO1999006559A1 (en) 1997-08-01 1999-02-11 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (gdf) receptors
DE19806040A1 (en) 1998-02-13 1999-09-09 Stork Mbk Gmbh Device and method for applying a medium to a substrate and system with several such devices
WO2000043781A2 (en) 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
WO1999042573A1 (en) * 1998-02-19 1999-08-26 Biostar Inc. Immunological methods to modulate myostatin in vertebrate subjects
WO2001005820A2 (en) * 1999-07-20 2001-01-25 Pharmexa A/S Method for down-regulating gdf-8 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCPHERRON ET AL: "Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 387, 1 May 1997 (1997-05-01), pages 83 - 90, XP002085797, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
AU2002339419A1 (en) 2002-12-03
CA2433644A1 (en) 2002-11-28
US20020127234A1 (en) 2002-09-12
EP1387695A2 (en) 2004-02-11
WO2002094315A2 (en) 2002-11-28
US7037501B2 (en) 2006-05-02
US20060088543A1 (en) 2006-04-27
US7488480B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
WO2002094315A3 (en) Myostatin immunoconjugate and its use for immunisation
WO2003039470A3 (en) Polyvalent immunogen of hiv
AU2001252525A1 (en) Method for production of enhanced traceable immunizing drinking water and other liquid and gas products, devices for production and use thereof, and use of the enhanced products for immunizing living beings
WO2001089457A3 (en) Thrombopoietin mimetics
EG23254A (en) Device and method for the generation of electricalenergy.
AU2002255791A1 (en) Coupled optical and optoelectronic devices, and method of making the same
NO20041882L (en) Methods for the treatment of ocular neovascular diseases.
WO2003045304A3 (en) Mutable vaccines
WO2002092122A3 (en) Use of osteopontin for the treatment and/or prevention of neurologic diseases
WO2001060347A3 (en) Method for treating ocular pain
BR0106097B1 (en) system to temporarily stop or abort a laser surgical procedure.
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2003024516A3 (en) Catheter having increased curve performance through heat treatment
TWI349525B (en) Immunization of plants against bacterioses
WO2004062583A3 (en) Vaccine and method for preventing biofilm formation
ZA200204019B (en) Combination treatment for alcoholism and alcohol dependence.
NO20034123L (en) Procedure for the treatment of fuel
WO1999057278A3 (en) IMMUNIZATION AGAINST AND TREATMENT FOR INFECTION BY $i(H.PYLORI)
WO2005016952A3 (en) Polyvalent immunogen
GB2424848B (en) Method of forming member, valve guide and method of forming the valve guide, and method of forming tubular member
EP1032583A4 (en) Active immunization against angiogenesis-associated antigens
AU2002339189A8 (en) Coating of optical device facets at the wafer-level
MXPA03004019A (en) Passivation method.
ZA200102636B (en) Method of treating a parasitic infection.
ITMI20031766A1 (en) DEVICE AND PROCEDURE FOR THE CLOSURE OF AMPOULTS BY LASER IRRADIANCE.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2433644

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2002752252

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002752252

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002752252

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP